Advertisement
A quick and easy way to share information about the latest colorectal research trials? I’m hoping the newly established #CRStrials fills that need.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The reason I came up with this Twitter account was to fill a gap. Colorectal surgeon Richard Brady in the UK started Colorectalsurgery to unite colorectal surgeons in clinical practice. He then started #ColorectalResearch to help disseminate recent research results. I thought of #CRStrials to network people participating in research before the research starts and while it’s underway.
#CRStrials has three main purposes:
To help accrue patients. When you’re starting a trial, you may overestimate the number of potentially eligible patients. This new innovative unique resource can help clinicians disseminate news of their participation in trials to help increase accrual.
To inform patients about trials. Whether a patient has ulcerative colitis or morbid obesity, many of them want to find out what’s the latest out there besides standard treatments. While there’s always clinicaltrials.gov, you really have to know what you’re looking for and it’s a bit cumbersome. #CRStrials will simply advertise high-level details, obviously continuously respecting HIPAA-compliance and study sponsor confidentiality.
To help industry. This resource can also help those who are looking to sponsor any colorectal-related research trials.
Thanks to Debby Keller, of Columbia University and University College London, we’ve gotten #CRStrials up and running and I’m enjoying serving in an advisory role. My appreciation as well to Emre Gorgun, MD, one of the colorectal surgeons who I asked to join the founding advisory group.
Advertisement
Our first tweet chat in January was well received by over 1,800 impressions and accordingly we’re hosting a second on Feb. 1, featuring myself, Dr. Keller, Dr. Karen Zaghiyan, and special guest Dr. Kat Baker.
Future chats will feature specific clinical trials.
So far, the response has been tremendous. If it goes well, we can expand it beyond colorectal surgery to other surgical areas and potentially beyond to medical specialties.
Advertisement
Advertisement
Findings could help identify patients at risk for poor outcomes
Findings also indicate reduced risk of serious liver events
Promising results could lead to improved screening, better outcomes
Significant improvement in GCSI scores following treatment
Despite benefits, vaccination rates remain low for high-risk population
Findings show greater reduction in CKD progression, kidney failure than GLP-1RAs
Findings indicate clinical decision making should not be driven by initial lesion size
Cleveland Clinic study finds that durable weight loss is key to health benefits